Clinical Development Hub
Local Demo
Home/country planning

Country Planning

Country strategy including regulatory lead times, startup productivity, and supply readiness. This workspace exists to enforce consistent clinical execution with accountable ownership, governed evidence, and inspection-ready traceability across the study lifecycle. It supports business and regulatory requirements by connecting operations, quality, submissions, and financial controls in a single system where handoffs are explicit and auditable. Users can proceed by filtering scope, reviewing linked artifacts and actions, and routing escalations with defined approval gates and signature meaning.

Country Strategy Alignment

Planned Countries
40
Regulatory Lead-Time
26d
Supply Readiness
84%

Country Start-Up Constraints

US
CA
GB
DE
FR
ES
IT
NL
BE
SE
NO
DK
FI
PL
CZ
AT
US | STUDY-0001Reg lead-time 20d | supply readiness watch
CA | STUDY-0002Reg lead-time 21d | supply readiness green
GB | STUDY-0003Reg lead-time 22d | supply readiness green
DE | STUDY-0004Reg lead-time 23d | supply readiness watch
FR | STUDY-0005Reg lead-time 24d | supply readiness green
ES | STUDY-0006Reg lead-time 25d | supply readiness green
IT | STUDY-0007Reg lead-time 26d | supply readiness watch
NL | STUDY-0008Reg lead-time 27d | supply readiness green
Access & Governance Controls
RBAC+ABACStudy Firewall Active

Operational Controls

Study firewalling chips highlight boundary, country constraints, and vendor partition rules.

Actions requiring GxP control include a human review checkpoint and e-signature meaning capture.

Every state change writes immutable audit evidence with actor, timestamp, and object reference.

Next Actions

Filter to portfolio/program/study context.

Open linked tasks, risks, and document evidence.

Escalate blocked items through governed workflow.